January 11, 1994 |
BioSource International Inc., a Camarillo producer of immunological reagents and test kits used in biomedical research, reports that warrants to purchase 700,000 shares of its common stock were exercised last month for a total price of $932,000. James Chamberlain, president and chief executive, said the purchases mean "practically all" of BioSource's outstanding warrants have been exercised.
May 17, 1994
BioSource International Inc., the Camarillo-based supplier of biomedical research products, said its net income for the first quarter that ended March 31 was $162,463, up slightly from $160,216 in the same quarter a year earlier. Revenue in the first quarter increased 22% to $1.54 million from $1.26 million the year before. The company said it reduced its administrative and selling costs from the first quarter last year, and more than doubled spending for research and development.
August 16, 1994
BioSource International Inc., a Camarillo-based supplier of reagents and test kits used in biomedical research, reported a $163,474 profit for the second quarter that ended June 30, more than four times the $40,103 in earnings reported in the year-earlier period. Revenue in the latest quarter was $1.71 million, up 26% from revenue of $1.35 million reported a year earlier. For the first six months of 1994, the company reported earnings of $325,941 on revenue of $3.
August 10, 1993
BioSource International Inc. said it entered an agreement with Vienna-based Bender MedSystems to develop four new tests to detect and measure levels of antibodies in biomedical tests involving mice. Camarillo-based BioSource will obtain and produce the basic materials and develop protocols for the test kits, which are likely to be used in the study of inflammatory disorders, cancer and AIDS. Bender MedSystems, a subsidiary of the Boehringer-Ingleheim Group, will manufacture the kits in Europe.
July 11, 1995
BioSource International Inc. has ended discussions regarding the acquisition of Operon Technologies Inc., the company has announced. BioSource announced the signing of a letter of intent in May to acquire Operon, a privately held firm with headquarters in Alameda, Calif. The transaction was expected to be completed by June 30. "We continue to feel that Operon's current product mix, manufacturing capability and scientific team would be an excellent fit with BioSource," James H.
May 4, 1993 |
Camarillo-based BioSource Industries Inc. says the final regulatory hurdle has been removed to its proposed merger with Burlingame-based Tago Inc. James H. Chamberlain, BioSource's president and chief executive, said the Securities and Exchange Commission approved the registration of securities to be issued to shareholders of the merged company, which will be called BioSource International Inc.